Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02685605 · ClinicalTrials.gov registry record · Phase 3
Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
A Phase 3 study of Glioblastoma, sponsored by Universitätsmedizin Mannheim.
- Active
- Registry status
- Phase 3
- Development phase
- 314
- Enrollment target
- 19
- Study locations
NCT02685605: Active Phase 3 study of Glioblastoma, sponsored by Universitätsmedizin Mannheim.
NCT02685605 is a Phase 3 study of Glioblastoma that is active but no longer recruiting, run by Universitätsmedizin Mannheim. The registered enrollment target is 314 participants, above the 107-participant average among 199 other Glioblastoma trials with a reported enrollment target (193% higher). The trial reports 19 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02685605, a Phase 3 study of Glioblastoma, is active but no longer recruiting, sponsored by Universitätsmedizin Mannheim.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 314 participants
- Enrollment target
- 19
- Study locations
Study Summary
INTRAGO II resembles a multicentric, prospective, randomized, 2-arm, open-label clinical phase III trial which tests if the median progression-free survival (PFS) of patients with newly diagnosed glioblastoma multiforme (GBM) can be improved by the addition of intraoperative radiotherapy (IORT) to standard radiochemotherapy.
Primary Outcome
Determined according to modified Response Assessment in Neuro-Oncology (RANO) criteria and serial perfusion imaging
Conditions Studied
Interventions
- DRUG Temozolomide
- PROCEDURE Standard surgery
- RADIATION Intraoperative radiotherapy
- RADIATION Radiochemotherapy
Study Locations (19)
Other
- Hospital Alemão Oswaldo Cruz - São Paulo
- Beijing Tian Tan Hospital, Capital Medical University - Beijing
- University Hospital Augsburg - Augsburg
- Charité - Universitätsmedizin - Berlin
- St. Georg Hospital - Leipzig
- University Hospital Mannheim - Mannheim
- Technical University of Munich (TUM), Department of Radiation Oncology - Munich
- Klinikum Stuttgart - Stuttgart
- Helios University Hospital Wuppertal - Wuppertal
- Gangnam Severance Hospital, Yonsei University College of Medicine - Seoul
- Catalan Institute of Oncology (ICO) - Barcelona
- Hospital Reina Sofia - Córdoba
- The London Clinic - London
New York
- Long Island Jewish Medical Center, North Shore University Hospital - Lake Success
- Lenox Hill Hospital, Hofstra Northwell School of Medicine - New York
Arizona
- Barrow Neurological Institute (SJHMC) - Phoenix
Illinois
- Stritch School of Medicine Loyola University - Maywood
West Virginia
- West Virginia University - Morgantown
Quebec
- Montreal Neurological Institute and Hospital - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2016-12-09 |
| Est. Completion | 2026-06 |
| Phase | Phase 3 |
What the registry record for NCT02685605 still lists
NCT02685605 is an interventional study that assigns participants to a tested intervention. The registered 314 participants enrollment target is mid-sized for trials with a published cap, above the 107-participant average among 199 other Glioblastoma trials with a reported enrollment target (193% higher).
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 4 interventions - of which Temozolomide is the first listed.
NCT02685605 lists 19 locations in 6 states (Other, New York, Arizona).
Frequently Asked Questions
What is clinical trial NCT02685605 about?
NCT02685605 is a clinical study titled "Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme". INTRAGO II resembles a multicentric, prospective, randomized, 2-arm, open-label clinical phase III trial which tests if the median progression-free survival (PFS) of patients with newly diagnosed glioblastoma multiforme (GBM) can be improved by the addition of intraoperative radiotherapy (IORT) to s...
What is the current status of trial NCT02685605?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 314 participants. The study started on 2016-12-09. Estimated completion is 2026-06.
What conditions does trial NCT02685605 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT02685605?
The interventions under investigation include: Temozolomide (DRUG), Standard surgery (PROCEDURE), Intraoperative radiotherapy (RADIATION), Radiochemotherapy (RADIATION).
Who is sponsoring clinical trial NCT02685605?
This trial is sponsored by Universitätsmedizin Mannheim, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02685605 being conducted?
This trial has 19 study locations across Arizona, Illinois, New York, West Virginia, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02685605's enrollment target sits among peer trials
314 18th of 199 higher than 182 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
RECRUITING · Phase 3
-
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
RECRUITING · Phase 3
-
Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients
RECRUITING · Phase 3
-
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
RECRUITING · Phase 3
-
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
RECRUITING · Phase 3
-
Tofacitinib in Recurrent GBM Patients
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03866382 · 314 participants · Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- NCT04500756 · 314 participants · Phase 2
Limiting AAA With Metformin (LIMIT) Trial
- NCT06167746 · 314 participants · Phase 3
iCare4Me Transitions
- NCT06883097 · 314 participants · NA
Quitting Matters Human Immunodeficiency Virus Hybrid Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI